Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88:: Effect on survival in patients with septic shock
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88:: Effect on survival in patients with septic shock
复制标题
DOI：
10.1097/01.ccm.0000105581.01815.c6
复制
发表时间：
2004-01-01
影响因子：
8.8
通讯作者：
Grover, R
中科院分区：
文献类型：
--
作者：
López, A;Lorente, JA;Grover, R
Objective: To assess the safety and efficacy of the nitric oxide synthase inhibitor 546C88 in patients with septic shock. The predefined primary efficacy objective was survival at day 28.Design: Multiple-center, randomized, two-stage, double-blind, placebo-controlled, safety and efficacy study.Setting: A total of 124 intensive care units in Europe, North America, South America, South Africa, and Australasia.Patients: A total of 797 patients with septic shock diagnosed for
